Close Menu


Among the findings from the ongoing study was the suggestion of an anti-VEGF effect in the majority of treated patients.

The data, Tekmira President and CEO Mark Murray said in a statement, "are the first demonstration that RNAi is efficacious in an otherwise lethal primate infectious disease setting," and support the utility of RNAi in infectious diseases.

The new data in pulmonary injury and emphysema provide "support for additional clinical applications of this drug, such as treatment of acute and chronic lung injury," according to a company official.

IP Update: May 20, 2010


USPTO Publishes Three Patents, Six Patent Applications Related to RNAi

Under the deal, Bristol-Myers Squibb will use siRNAs formulated with Tekmira's stable nucleic acid-lipid particle-based delivery technology to "validate the function of certain cellular targets."

Safety data show no dose-limiting toxicities in any cohort, Quark said, supporting the drug's continued development.

The deal, which is independent of another arrangement under which Silence is developing siRNA drugs against AstraZeneca-specified targets, has been extended for one year.

According to MDRNA, the application claims siRNAs and delivery systems with therapeutic potential.

However, the company will most likely require an additional infusion of capital before it can move any of its programs into the clinic, Traversa President and CEO Hans Petersen said.

Under the expanded deal, Silence will demonstrate functional delivery of siRNAs against new targets selected by Dainippon.


Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.